LynparzaRecentin Combo Fails In Phase III PSR Ovarian Cancer
Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer
12:50 EDT 15 Mar 2020 |
SCRIP
Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain;...
Original Article: Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer
More From BioPortfolio on "Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer"